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Abstract
Atrial fibrillation affects at least 1% of the population and causes marked society-wide morbidity
and mortality. Current management of atrial fibrillation including antithrombotic therapy and
management of concomitant conditions in all patients, rate control therapy in most patients, and
rhythm control therapy in patients with severe atrial fibrillation-related symptoms can alleviate
atrial fibrillation-related symptoms but can neither effectively prevent recurrent atrial fibrillation
nor suppress atrial fibrillation-related complications. Hence, there is a need for better therapy of
atrial fibrillation.
The etiology of atrial fibrillation is complex. Most of the causes of atrial fibrillation which are known
at present perpetuate themselves in vicious circles, and presence of the arrhythmia by itself causes
marked damage of atrial myocardium. These pathophysiological insights suggest that early diagnosis
and comprehensive therapy of atrial fibrillation, including adequate therapy of all atrial fibrillation-
causing conditions, rate control, and rhythm control therapy, could help to prevent progression of
atrial fibrillation and reduce atrial fibrillation-related complications. Such a therapy should make use
of safe and effective therapeutic modalities, some of which have become available recently or will
become available in the near future. The hypothesis that early diagnosis and early, comprehensive
therapy of atrial fibrillation can improve outcomes requires formal testing in controlled trials.
Commentary
Atrial fibrillation (AF) is the most common sustained
arrhythmia and affects at least 1% of the population,
amounting to 5.5 to 7 million patients with AF in Europe
[1,2]. AF is characterized by very rapid, irregular electrical
activation of the atria (350 to 400 bpm), resulting in 1)
loss of coordinated contraction and transport function in
the atria and 2) irregular ventricular rate and loss of ven-
tricular rate adaptation to increased demands (arrhythmia
absoluta). In an ageing population, the prevalence and
incidence of AF will increase dramatically in the next dec-
ades [2,3]. Unlike most other supraventricular tachyar-
rhythmias, atrial fibrillation can usually not be cured
[4,5]. Rather, most patients progress from paroxysmal AF,
that is, AF that alternates with periods of sinus rhythm, to
sustained forms (Figure 1), even when currently available
therapeutic options are applied. This sobering finding is
aggravated by the dramatic consequences that AF implies
in affected individuals and for society (Table 1).
One of the reasons why AF is so difficult to cure is proba-
bly the complex etiology of the arrhythmia as recently
outlined in two consensus conferences on AF [6,7]: AF can
be caused by atrial structural damage conferred by cardiac
or extracardiac disease and rapid irregular ventricular rate
[8,9], a sign of natural ageing of the heart, and an electrical
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accident due to abnormal electrical function of the heart.
Furthermore, AF perpetuates itself by altering electrical
function of the atria (Figure 2). Unfortunately, all of these
mechanisms form vicious circles and are severely aggra-
vated once AF has manifested. Usually, several of these
factors have to concur before the arrhythmia develops.
Current management of AF patients
Adequate therapy of patients with AF considers stroke
risk, often requiring continuous oral anticoagulation
[4,10-12], AF-related symptoms as, for example, esti-
mated by the European Heart Rhythm Association
(EHRA) score [13], ventricular rate during AF, and the risk
for AF-related complications [4]. In addition, all condi-
tions that can contribute to AF and to AF-related compli-
cations require adequate management [14]. On top of
these therapeutic interventions, rhythm control therapy
should be considered when AF-related symptoms are
severe. The decision for rhythm control is based on indi-
vidual preferences of the patient and often also considers
the perceived risk of AF recurrences [4,5,15-17].
Potential benefits of sinus rhythm
Potentially, sinus rhythm should be able to prevent the
adverse outcomes of AF: In cohort studies, AF associates
with death and stroke in the population [1], and AF asso-
ciates with worse prognosis than sinus rhythm in the set-
ting of an acute myocardial infarction [18] or in patients
with heart failure [19-21]. The recently published ATH-
ENA trial also supports this notion by showing that dron-
edarone, an antiarrhythmic drug with additional rate-
slowing properties, prevents a composite outcome of car-
diovascular hospitalizations and death [22].
Table 1: Consequences of AF in affected individuals.
Death death rates are doubled in AF patients. This effect is independent of known other cardiovascular risk factors or 
concomitant disease. Death rates are also increased in patients with a myocardial infarction or in heart failure patients 
when AF is added to their disease pattern.
Stroke Approximately every 4th stroke is due to AF. The possibility of "silent", undiagnosed AF - which is common in trials using 
systematic ECG monitoring -, may suggest that AF is also a potential cause of "cryptogenic" stroke.
Quality of life is markedly reduced in AF patients, due to their symptoms but possibly also due to an unrecognized effect of AF on 
social functioning, cerebral function, or other factors. It is conceivable that AF-related hospitalizations contribute to 
reduced quality of life in AF patients.
Rhythm AF causes arrhythmia absoluta and impairs rate adaptation of heart beat to demand. Abnormal heart rate can cause 
symptoms ranging from palpitations to acute chest pain or cardiac decompensation, especially when ventricular rate is 
inadequate.
Left ventricular function is impaired by AF, especially in patients with known heart failure or with a tendency to develop heart failure. Restoring 
sinus rhythm and maintaining effective heart rate control can prevent such AF-induced decline of heart failure.
Other relevant outcomes in AF are indicated in [6,13].
Natural time course of atrial fibrillation Figure 1
Natural time course of atrial fibrillation. Shown is a typical chaotic pattern of time in atrial fibrillation (black) and time in 
sinus rhythm (grey) over time (x-axis). Atrial fibrillation progresses from undiagnosed to first diagnosed, paroxysmal, persist-
ent, to permanent. Flashes indicate cardioversions as examples for therapeutic interventions that influence the natural time 
course of the arrhythmia. Reproduced with permission from [13].BMC Medicine 2009, 7:72 http://www.biomedcentral.com/1741-7015/7/72
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These observations have spurred several controlled trials
testing whether rhythm control therapy improves out-
comes in AF patients when compared to rate control ther-
apy: At least six controlled trials have been completed and
published [17,23-27]. None of these trials showed an
advantage of rhythm control over rate control, and a meta
analysis even suggested a slight benefit of rate control
therapy [28].
Why does rhythm control therapy not translate into better 
outcomes?
Several issues warrant consideration in the struggle to
explain this unexpected finding.
1. The therapies applied in the published trials were not
effective enough to really maintain sinus rhythm: In the
large Atrial Fibrillation Follow-up Investigation of
Rhythm Management (AFFIRM) trial, sinus rhythm rate
was 60% in the rhythm control group at the end of follow-
up, and 30% in the rate control group [24]. In the more
recent Atrial Fibrillation and Congestive Heart Failure
(AF-CHF) trial, sinus rhythm rates were around 60% in
the rhythm control group and 25% in the rate control
group during follow-up [17].
2. Antiarrhythmic drugs, especially when used as long-
term therapy, carry a risk of proarrhythmia.
3. Apparent presence of sinus rhythm may have triggered
withdrawal of prognostic therapy, for example, anti-
thrombotic therapy, despite the fact that AF may recur
silently and cause severe complications.
4. Antiarrhythmic drugs only target one of the mecha-
nisms that cause AF (blue circle in Figure 2). Catheter
ablation of AF mainly eliminates focal triggers of AF (red
circle in Figure 2). A combination therapy antiarrhythmic
drugs and AF ablation procedures has not been tested, let
alone a comprehensive therapy including management of
other cardiac disease.
5. Many patients were enrolled in the published trials at
an advanced stage of AF, often with a long AF history.
Can early therapy of AF help to improve efficacy and 
safety of rhythm control therapy?
Atrial fibrillation sustains itself through a complex process
that is initiated by high atrial rate, cytosolic calcium over-
load, metabolic depletion, contractile dysfunction, and
counter-regulatory processes that attempt to maintain
function of the myocardial cells [6]. When AF is main-
tained for short periods of time only (minutes to hours),
these processes can be reversed by restoring sinus rhythm.
After several days or even weeks of the arrhythmia, irre-
versible atrial damage already develops. Early restoration
and maintenance of sinus rhythm could prevent such irre-
versible AF-induced atrial damage.
Clinical observations support this concept: Conversion of
AF to sinus rhythm by antiarrhythmic drugs is relatively
effective when AF duration is short [29,30], but almost
never effective when AF duration exceeds two weeks [4].
On a similar line, catheter ablation has a higher success
Interdependence of four of the main mechanisms that con- tribute to the initiation and maintenance of atrial fibrillation Figure 2
Interdependence of four of the main mechanisms 
that contribute to the initiation and maintenance of 
atrial fibrillation. Each circle represents a relevant factor 
that may initiate or perpetuate atrial fibrillation (AF): The 
blue circle represents shortening of the atrial action potential 
and effective refractory period (electrical remodelling), the red 
circle focal triggers of AF, the blue circle ultrastructural 
changes conferred by AF (structural remodelling), and the 
brown circle the bidirectional damage conferred by left ven-
tricular and (left) atrial function during AF. The pie chart 
within each circle gives educated guesses as to how often this 
pathophysiological mechanism will be due to AF itself (black 
pie piece), genetic predispositions (light blue), a response of 
the atria to stressors such as hypertension, diabetes, or val-
vular heart disease (grey), and ageing (light green). In an indi-
vidual patient (but also in a specific experimental model), AF 
will be due to a blend of these different factors as indicated 
by the blended overlap between the circles. Reproduced 
with permission from [6].BMC Medicine 2009, 7:72 http://www.biomedcentral.com/1741-7015/7/72
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rate in patients with paroxysmal AF compared to patients
with sustained forms of the arrhythmia [31]. Hence,
rhythm control therapy may become more effective when
it is initiated early [32].
Can earlier diagnosis of AF help to prevent AF-related 
complications?
It is very likely that, in addition to the patients with
known AF, a large number of additional patients suffer
from undiagnosed, silent AF [13]. An active search for AF
in patients at risk for the arrhythmia may allow diagnosis
of silent AF before the first complication occurs [33,34].
While conventional Holter electrocardiogram (ECG)
recordings have a low diagnostic yield for paroxysmal AF,
newer technologies like patient-operated or telemetric
ECG systems, long-term Holter monitors, or even
implanted ECG monitors carry the promise of allowing an
early diagnosis of silent AF [6,35-37]. Early diagnosis of
AF would not only allow the early initiation of rate and
rhythm control therapy, but could also help to prevent
AF-related complications, for example, by timely initia-
tion of antithrombotic therapy.
Can rhythm control therapy be delivered safely?
Early therapy of AF, especially therapy aiming at prevent-
ing complications rather than alleviating symptoms,
needs to be reasonably safe, and actually safer than ther-
apy that is demanded by a suffering patient. Safety has,
however, been a major consideration in antiarrhythmic
drug therapy [38]. One example is the AFFIRM trial popu-
lation in which presence of sinus rhythm during follow-
up associated with better survival, while therapy with
antiarrhythmic drugs associated with earlier death [39].
One potential way to resolve this difficulty is to limit
antiarrhythmic drug therapies to periods when their
effects are really needed [40-42]. Another perspective may
be to develop new, safer antiarrhythmic agents [22]. At
present, the safety profile of catheter ablation of AF in
relation to its efficacy has not been clearly delineated: Suc-
cess rates are high, especially in paroxysmal AF patients,
but complication rates are not negligible [43-45], and
although most complications can be managed without
long-term sequelae, there is a residual death rate induced
by AF ablation [45].
Summary
Although atrial fibrillation is clearly associated with severe
consequences such as stroke, heart failure, and death, cur-
rent rhythm management in AF patients does not trans-
late into improved outcomes. Earlier initiation of rhythm
control therapy, especially when embedded in a compre-
hensive AF management strategy, has the potential to
maintain sinus rhythm more effectively, to disrupt the
vicious circles that maintain AF and cause its complica-
tions, and to prevent AF-related complications before they
occur. Potentially, a combination of intermittent, short-
term antiarrhythmic drug therapy, antiarrhythmic drug
therapy using new, potentially safer agents, and catheter
ablation of AF could be components of early rhythm con-
trol therapy. Given the potential benefits and risk of such
a therapy, there is a clear need to test whether early
rhythm control therapy of AF can improve outcomes in AF
patients.
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